Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANEXSIA 5/325 vs LANOXICAPS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation (rate control)
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Terminal elimination half-life is approximately 5-7 days (120-168 hours) in patients with normal renal function; prolonged in renal impairment, necessitating dose adjustment.
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Primarily renal excretion as unchanged drug; minor hepatic metabolism via CYP3A4 and glucuronidation.
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Digitoxin is primarily excreted via the kidneys (approx. 70-80%) as unchanged drug and metabolites; the remainder undergoes biliary/fecal elimination (approx. 20-30%).
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
Digitoxin is approximately 90-97% bound to serum proteins, primarily albumin.
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Volume of distribution is approximately 0.6 L/kg, indicating extensive tissue binding and distribution; the large Vd reflects accumulation in tissues like myocardium and skeletal muscle.
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
Oral bioavailability is virtually 100% (90-100%) for Lanoxicaps (digitoxin), with consistent absorption from the gastrointestinal tract.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
For e GFR <50 m L/min, reduce dose by 50% or extend dosing interval: e GFR 35-50 m L/min: 0.125 mg every 24-48 hours; e GFR 10-34 m L/min: 0.125 mg every 48-72 hours; e GFR <10 m L/min: 0.125 mg every 72-96 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
Severe hepatic impairment (Child-Pugh class C) requires dose reduction by 50-75%; monitor digoxin levels. Avoid in fulminant hepatitis.
Not recommended for children under 18 years due to risk of respiratory depression.
Neonates: 4-6 mcg/kg/day; Infants: 6-10 mcg/kg/day; Children 1-5 years: 10-15 mcg/kg/day; Children 6-12 years: 8-10 mcg/kg/day; Adolescents: 3-5 mcg/kg/day. All doses given orally.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
Start at lower dose (0.0625-0.125 mg daily) due to reduced renal function and lean body mass; monitor serum creatinine and digoxin levels.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Toxicity: Narrow therapeutic index; monitor serum levels; avoid in patients with ventricular fibrillation or outflow obstruction.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
Monitor for digitalis toxicity (anorexia, nausea, visual disturbances, arrhythmias). Adjust dose in renal impairment, hypokalemia, hypomagnesemia, hypercalcemia, and hypothyroidism.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
Ventricular fibrillation,Hypersensitivity to digitalis glycosides,Wolff-Parkinson-White syndrome with atrial fibrillation,Second- or third-degree AV block (without pacemaker),Hypertrophic obstructive cardiomyopathy
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
High-fiber foods (bran, oats) and certain foods containing pectin can reduce digoxin absorption; take Lanoxicaps on an empty stomach or at least 1 hour before or 2 hours after meals. St. John's Wort may decrease digoxin levels. Avoid licorice root, which can cause hypokalemia and increase toxicity. Consistent dietary potassium intake is important; avoid potassium supplements unless directed.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal bradycardia, low birth weight; therapeutic levels near toxic for fetus. Use only if maternal benefit outweighs risk.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Digoxin is excreted into breast milk at low levels (M/P ratio ~0.6–0.9); infant exposure is subtherapeutic. Considered compatible with breastfeeding, but monitor infant for signs of digoxin toxicity (e.g., arrhythmias, nausea).
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Increased volume of distribution and renal clearance in pregnancy may lower digoxin levels; dose adjustment often needed in third trimester. Monitor levels frequently and increase dose if subtherapeutic. Postpartum, reduce dose as clearance normalizes.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Lanoxicaps (digoxin) has a high bioavailability (90-100%) compared to standard digoxin tablets; adjust dose when switching formulations to avoid toxicity. Monitor renal function and electrolytes (especially potassium, magnesium, calcium) closely; hypokalemia increases digoxin toxicity risk. Digoxin toxicity can present with arrhythmias (e.g., bidirectional ventricular tachycardia, atrial tachycardia with block) and visual disturbances (yellow-green halos). Use digoxin-specific Fab fragments for life-threatening toxicity. Therapeutic drug monitoring: draw levels at least 6-8 hours after dose; target 0.5-0.9 ng/m L for heart failure, 0.8-2.0 ng/m L for atrial fibrillation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
Take exactly as prescribed; do not miss doses or double up. If a dose is missed, skip it unless close to next dose.,Do not switch between Lanoxicaps and standard digoxin tablets without your doctor's approval due to different absorption.,Report symptoms of toxicity: nausea, vomiting, diarrhea, confusion, visual changes (blurred vision, yellow-green halos), or irregular heartbeat.,Keep regular appointments for blood tests to monitor digoxin levels, kidney function, and electrolytes.,Avoid over-the-counter medications, especially antacids, kaolin-pectin, and some laxatives, which can affect absorption.,Maintain consistent dietary intake of potassium-rich foods (bananas, oranges) and avoid extreme changes in diet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANEXSIA 5/325 vs LANOXICAPS, answered by our medical review team.
ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. LANOXICAPS is a Cardiac Glycoside that works by Inhibition of Na+/K+-ATPase pump, leading to increased intracellular sodium and calcium, positive inotropy, and increased vagal tone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANEXSIA 5/325 and LANOXICAPS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. The standard adult dose of LANOXICAPS is: 0.125-0.25 mg orally daily, initially 0.25 mg daily in divided doses 3-4 times daily, maintenance 0.125-0.25 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANEXSIA 5/325 and LANOXICAPS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. LANOXICAPS is classified as Category C. FDA Pregnancy Category C. First trimester: digitalis glycosides cross placenta; animal studies show fetotoxicity, but no adequate human data. Second/third trimester: risk of fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.